Europe Veterinary Pharmaceuticals Market (2026 - 2033)

Europe Veterinary Pharmaceuticals Market Summary

The Europe veterinary pharmaceuticals market size was valued at USD 7.9 billion in 2025 and is projected to grow from USD 8.6 billion in 2026 to USD 17.1 billion by 2033, at a CAGR of 10.3% from 2026 to 2033. The growing awareness about zoonoses, the humanization of pets, the availability of pet insurance, and R&D initiatives by market players are the key factors anticipated to fuel market growth in the coming years.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

Market Concentration & Characteristics

The Europe veterinary pharmaceuticals market demonstrates a diverse competitive landscape, comprising established multinational animal health companies, specialized veterinary pharmaceutical manufacturers, and regional players offering vaccines, anti-infectives, parasiticides, anti-inflammatory drugs, biologics, and other veterinary medicines. In addition, key participants are benefitting from broad product portfolios, established relationships with veterinarians and distributors, strong research and development capabilities, and expertise in European regulatory requirements.

The degree of innovation in the Europe veterinary pharmaceuticals market is moderate to high, driven by combination parasiticides, targeted therapies, biologics, and improved formulations. For instance, in July 2025, Elanco Animal Health secured received European Commission approval for Zenrelia (ilunocitinib), a once-daily oral tablet for controlling pruritus associated with allergic dermatitis and clinical manifestations of atopic dermatitis in dogs aged at least 12 months. Such advances expand treatment options, support parasite control, and address health needs across companion and production animals.

To learn more about this report, Download Free Sample Report

The Europe Veterinary Pharmaceuticals Market indicates a moderate level of merger and acquisition (M&A) activity, characterized by targeted acquisitions of specialty medicines and established pharmaceutical portfolios. In addition, companies are seeking to expand their therapeutic offerings, gain access to niche treatments, and improve distribution across companion and livestock animal segments. For instance, in April 2025, Swedencare completed its acquisition of UK-based Summit Veterinary Pharmaceuticals, expanding its specialty veterinary medicine portfolio for dogs, cats, horses, and veterinary clinics. Such developments support portfolio diversification and access to specialized treatments.

Regulations have a high impact on the Europe Veterinary Pharmaceuticals Market because product marketing authorization, safety assessment, environmental risk evaluation, and post-marketing pharmacovigilance determine market entry and continued product availability. The EU Veterinary Medicinal Products Regulation (EU) 2019/6 establishes harmonized requirements while providing centralized and national authorization pathways. These requirements increase compliance costs and documentation requirements but support product quality, safety, and cross-border market access. Furthermore, restrictions on routine antimicrobial use and growth promotion affect demand for anti-infectives and encourage more targeted treatment approaches.

The threat of product substitutes in the Europe veterinary pharmaceuticals market is low to moderate, as alternative disease-prevention and animal-health management approaches can reduce pharmaceutical use in selected applications. Vaccination, improved farm biosecurity, hygiene, and better animal husbandry can lower the incidence of infectious diseases, while probiotics, prebiotics, bacteriophages, and immunomodulators are being investigated as alternatives to certain antimicrobial treatments.

Regional expansion in the Europe Veterinary Pharmaceuticals Market is driven by investments in manufacturing capacity, wider product distribution, and the expansion of established veterinary medicine portfolios across European countries. In addition, companies are strengthening regional production capabilities to meet demand for medicines used in companion and livestock animals, improve supply continuity, and serve export markets. For instance, in March 2025, Elanco initiated an expansion of its manufacturing facility in Huningue, France, with an investment of USD 39.5 million. The expansion supports the supply of companion-animal medicines, including antiparasitics and anti-inflammatory products, and strengthens the company's European manufacturing base.

Analyst Perspective

The Europe veterinary pharmaceuticals market is entering a phase where therapeutic specialization, product portfolio breadth, regulatory compliance, and distribution reach are becoming stronger determinants of competitive position than basic medicine availability. Established pharmaceutical categories, including parasiticides, anti-infectives, analgesics, and anti-inflammatory medicines, remain central to routine animal healthcare, while specialized treatments for chronic companion-animal conditions and disease management in production animals are creating opportunities for portfolio expansion. Manufacturers are competing through improvements in oral, injectable, and topical formulations, alongside branded and generic product offerings. At the same time, antimicrobial stewardship, pharmacovigilance requirements, generic competition, and differences in national market access are influencing product development and commercialization strategies across Europe.

Animal Insights

The production animal segment accounted for the largest share of 65.4% in 2025.The segment includes cattle, pigs, sheep, goats, poultry, and other livestock species that require pharmaceutical products to prevent and treat infectious diseases, parasitic infestations, inflammatory conditions, and other animal health disorders. The demand is increasing as commercial livestock producers seek to maintain herd and flock health, reduce mortality, improve productivity, and comply with animal health and food safety requirements. The growing use of parasiticides, anti-infectives, and anti-inflammatory drugs across European livestock farming is further supporting segment demand.

The companion animals segment is anticipated to register the fastest CAGR during the forecast period. The segment includes dogs, cats, horses, and other companion animals that require pharmaceutical products for the prevention and treatment of infectious diseases, parasitic infestations, inflammatory conditions, and chronic disorders. In addition, increasing pet humanization and growing demand for preventive treatments are supporting segment growth across Europe.

R&D Landscape

Research and development in the Europe veterinary pharmaceuticals market is being shaped by antimicrobial stewardship requirements, regulatory compliance, advances in diagnostic technologies, and demand for improved treatment outcomes. Regulation (EU) 2019/6 restricts the prophylactic use of antimicrobials and prohibits their use for growth promotion, creating opportunities for rapid diagnostic testing, preventive vaccines, and alternatives to conventional antibiotics.

To learn more about this report, Download Free Sample Report

In addition, key innovation areas include molecular diagnostics and biomarkers for early disease detection, analytical testing and regulatory validation, long-acting injectable and palatable formulations that improve treatment administration, and alternative therapies such as bacteriophages, probiotics, phytogenics, and immunomodulators. Digital technologies, including precision livestock monitoring, electronic prescribing, and automated pharmacovigilance systems, are supporting data-driven veterinary care and pharmaceutical safety management.

Product Insights

The parasiticides segment dominated the Europe veterinary pharmaceuticals market, accounting for 35.1% of the market in 2025. The segment is driven by the widespread need to prevent and treat endoparasitic and ectoparasitic infestations across companion and livestock animals. Dogs and cats require regular protection against fleas, ticks, mites, and intestinal worms, while livestock requires parasite control to maintain animal health, productivity, and welfare. In addition, the availability of oral, topical, and injectable parasiticides supports treatment adoption across European veterinary practices and livestock farms.

The other product anticipated to register the fastest CAGR during the forecast period. It comprises veterinary pharmaceutical products used to treat conditions outside the major therapeutic categories of parasiticides, anti-infectives, analgesics, and anti-inflammatory drugs. The segment is driven by the need to manage diverse health conditions across companion and livestock animals, including reproductive disorders, digestive problems, respiratory diseases, and conditions requiring anesthesia or sedation.

Drug Type Insights

The branded segment accounted for the largest market share of 58.6% in 2025. This is attributed to the presence of established veterinary pharmaceutical companies, strong brand recognition, and veterinarians' familiarity with existing products. Branded medicines benefit from established distribution networks, product quality standards, and government authorizations. In addition, continuous product development and the availability of medicines for a wide range of animal diseases also support demand throughout veterinary clinics, hospitals, and livestock farms.

The generics segment is projected to register the highest CAGR over the forecast period. The growth is supported by the lower cost of generic veterinary medicines compared with branded alternatives, making treatments more affordable for clinics, animal owners, and livestock producers. In addition, the availability of generic medicines also increases treatment options for common animal diseases. For instance, in April 2025, the European Medicines Agency published a positive opinion for Emevet, a generic veterinary medicine containing maropitant for treating conditions such as vomiting in animals. The availability of such products supports competition and access to affordable veterinary treatments across Europe.

Type Insights

The prescription segment accounted for the largest market share of 62.0% in 2025. This is attributed to the need for veterinary diagnosis and professional supervision when treating complex animal diseases. Prescription medicines are widely used to treat bacterial infections, inflammatory conditions, and other health problems requiring specific treatment plans. In addition, regulations governing the sale and use of certain veterinary medicines support demand through veterinary hospitals and clinics. The availability of prescription treatments for companion and livestock animals further contributes to segment growth.

The OTC segment is projected to register the highest CAGR over the forecast period. The segment is driven by rising pet ownership, greater awareness of animal health, and demand for accessible treatment options. OTC veterinary medicines allow animal owners to manage certain minor health conditions and routine healthcare needs without obtaining a prescription, where permitted by regulations. In addition, wider availability through veterinary pharmacies, retail outlets, and online channels is expected to improve product access. Growing interest in preventive animal healthcare is anticipated to support segment growth.

Route of Administration Insights

The oral segment accounted for the largest market share of 43.3% in 2025, driven due to the ease of administration, convenience, and wide availability of veterinary medicines in the form of tablets, capsules, liquids, and powders. Oral medicines are used to treat infections, digestive disorders, and other health conditions in companion and livestock animals. They allow pet owners to administer treatments at home and enable livestock producers to provide medicines through feed or drinking water, where appropriate. The increasing developments are further increasing the segment growth. For instance, in September 2026, the European Medicines Agency (EMA) recommended an update to the marketing authorization for Firocoxib CP-Pharma chewable tablets to add horses as a target species for treating pain and inflammation associated with osteoarthritis. This development supports the use of oral veterinary medicines across additional animal species.

The other routes segment is projected to register the highest CAGR over the forecast period. The other routes segment includes veterinary pharmaceutical products administered through ophthalmic, otic, intranasal, inhalation, rectal, vaginal/intrauterine, transdermal, and other specialized routes. The growth for these products is driven by the need for targeted treatment of eye and ear infections, respiratory conditions, and reproductive health problems in companion and livestock animals. These administration routes provide alternative treatment options when oral or injectable medicines are unsuitable or difficult to administer. Advancements in drug formulations and delivery systems are also supporting the availability of specialized veterinary medicines. The growing need for effective treatment across different animal species is expected to support segment growth in Europe.

Sales Channel Insights

The institutional sales segment led the Europe veterinary pharmaceuticals market, accounting for the largest revenue share of 42.6% in 2025. The segment is fueled by regular pharmaceutical purchases by veterinary hospitals, clinics, commercial livestock producers, and integrated farms. These buyers require medicines across various therapeutic categories to treat animal diseases and maintain animal health. The growing demand for companion animal healthcare and disease management in livestock operations further supports institutional purchases. In addition, established procurement relationships and the need for a consistent supply of veterinary medicines also contribute to segment growth. The segment is expected to maintain its leading position as veterinary professionals and organized livestock producers remain major purchasers of veterinary pharmaceutical products.

To learn more about this report, Download Free Sample Report

The e-commerce segment is expected to register the fastest CAGR over the forecast period, driven by the convenience of online purchasing, wider product availability, and home delivery of eligible veterinary pharmaceutical products. Online platforms allow companion animal owners to purchase routine healthcare products, including eligible parasiticides and other non-prescription medicines. The expansion of digital retail platforms and greater use of online shopping are also improving access to veterinary products across Europe. In addition, demand for recurring-use products supports repeat online purchases. However, the sale of prescription veterinary medicines remains subject to applicable European and national regulations, which influence the range of products available through e-commerce channels.

Country Insights

Germany’s veterinary pharmaceuticals marketis driven by companion animal population and demand for preventive treatments and medicines for acute and chronic conditions. According to the ZZF, Germany had 15.7 million cats and 10.0 million dogs in 2025, with companion animals present in 43% of households. This population supports recurring demand for parasiticides, anti-infectives, analgesics, anti-inflammatory products, and specialty medicines distributed through veterinary hospitals and clinics. Pharmaceutical innovation for chronic conditions is expanding treatment options for companion animals. For instance, in July 2025, the European Commission granted marketing authorization to Numelvi (atinvicitinib), an oral veterinary medicine for dogs experiencing pruritus associated with allergic dermatitis and clinical manifestations of atopic dermatitis. This development expands the availability of targeted dermatological treatments and supports demand for prescription veterinary medicines in Germany.

The UK veterinary pharmaceuticals market is supported by demand for companion-animal treatments and pharmaceutical interventions across livestock production. Routine parasite prevention, infection management, pain control, and vaccination programs contribute to medicine procurement by veterinary practices, animal hospitals, and livestock producers. The need to manage infectious diseases in cattle and sheep sustains demand for parasiticides, anti-infectives, anti-inflammatory medicines, analgesics, and vaccines to reduce disease-related health risks and production losses. In companion animals, the management of chronic conditions and acute illnesses further supports demand for prescription veterinary medicines, while established veterinary healthcare infrastructure facilitates access to a broad range of pharmaceutical products.

The Sweden veterinary pharmaceutical market is expected to grow at the fastest CAGR over the forecast period. The country is driven by demand for companion-animal healthcare, livestock disease management, and preventive treatments. In addition, rising demand for parasiticides, and medicines for infectious and chronic diseases supports pharmaceutical consumption across veterinary clinics and hospitals. In livestock, cattle health management and disease prevention contribute to demand for veterinary medicines. Furthermore, Sweden’s strict regulatory requirements influence prescribing patterns and product selection, creating opportunities for manufacturers of approved vaccines, targeted therapies, and other preventive treatments.

Key Europe Veterinary Pharmaceuticals Company Insights

The Europe veterinary pharmaceuticals market is highly competitive, with leaders competing through broad portfolios, strong R&D capabilities, regulatory approvals, manufacturing scale, and extensive veterinary distribution networks. Competition is further intensified by specialized players targeting specific vaccine technologies, species, and regional markets. Market share remains distributed across leading companies rather than dominated by a single participant, creating a fragmented competitive structure.

Key Europe Veterinary Pharmaceuticals Companies

• Merck & Co., Inc.,

• Ceva

• Vetoquinol

• Zoetis Services LLC

• Boehringer Ingelheim International GmbH

• Elanco

• Virbac

• Calier

• Bimeda Corporate

• Prodivet Pharmaceuticals SA/NV

Recent Developments:

• In June 2026, Alivira Animal Health, a subsidiary of Viyash Scientific Limited, signed a binding agreement to acquire 100% of Italy-based BioForLife Italia, a company specializing in companion-animal medicines, nutritional supplements, and rapid diagnostic tests. The acquisition is intended to expand Alivira’s presence in Italy, facilitate the introduction of its pipeline products, and broaden its companion-animal healthcare portfolio, supporting growth in the Europe veterinary pharmaceuticals market.

• In 2025, the European Medicines Agency (EMA) reported expanded indications for Bravecto TriUNO for treating Angiostrongylus vasorum infections in dogs and NexGard and NexGard Spectra for reducing the risk of certain parasite-transmitted infections. Such developments support demand for parasite-control products across Europe.

Europe Veterinary Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Europe veterinary pharmaceuticals market report based on animal type, product, drug type, type, route of administration, sales channel, and country.

• Animal Outlook (Revenue, USD Million, 2021 - 2033)

  • Production Animals

    • Poultry

    • Swine

    • Bovine

    • Ovine & Caprine

    • Others

  • Companion Animals

    • Canine

    • Feline

    • Equine

    • Others

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Parasiticides

  • Anti-infectives

  • Anti-inflammatory

  • Analgesics

  • Other Products

• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Branded

  • Generics

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Prescription

  • OTC

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Oral

  • Injectable

  • Topical

  • Other Routes

• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Institutional Sales

  • Veterinary Pharmacies & Retail

  • E-Commerce

  • Other Channels

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

Research Methodology

The Europe veterinary pharmaceuticals market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each Europe veterinary pharmaceuticals segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report